The FDA should require clinical trials in perioperative therapy for non-small cell lung cancer (NSCLC) to address the individual contributions of neoadjuvant and adjuvant treatment to outcomes, an ...
ExoLuminate: An observational registry study for detection of pancreatic adenocarcinoma (PDAC) in high-risk or clinically suspicious patients. Targeting minimal residual disease (MRD) in resected RAS ...
Adding perioperative durvalumab (Imfinzi) to neoadjuvant chemotherapy significantly improved survival outcomes in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), a phase III ...
IMFINZI was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings. Further, adding IMFINZI to neoadjuvant chemotherapy was consistent with the ...
Medication reconciliation is an important part of maintaining medication safety, and the Association of periOperative Registered Nurses calls on all perioperative RNs to focus on safety during the six ...
JMIR Publications is pleased to announce a new theme issue titled “Perioperative Blood Management” in JMIR Perioperative Medicine. The premier, peer-reviewed journal is indexed in PubMed and focuses ...
Anesthesiologists play a crucial role in safeguarding perioperative and critical care. However, low- and middle-income ...
MedPage Today on MSN
Gastric cancer's individualized patient-centered treatment approach
The specifics of endoscopic/surgical resection and perioperative treatment ...
WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered perioperatively in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results